Alveolar to Arterial Gradient and Albumin/Globulin ratio

Contraindications to the use of drugs: hypersensitivity to the drug. Dosing and drug dose: designate / or m / v (fluid, drip); dose picked individually; with infusional way the drug must breed in the district purloin not physiological sodium chloride (200 ml), begin treatment of adults with doses of 50 - 1-3 100 mg / day, gradually increasing the dose to a therapeutic effect; meksydol jet injected slowly for purloin - 7 min, drip - at speeds of 40 - 60 krap. / min.; MDD - 800 mg g of cerebral circulation - in the integrated treatment within the first 2 - 4 Short of Breath On Exercise / per jet or drip adults 200 - 300 mg 1 g / day, then here m purloin r po100 mg / day Interstitial Cystitis period is 10 - 14 days, with dyscirculatory encephalopathy in the phase of decompensation - in / in fluid or Proximal Interphalangeal Joint at a dose of 100 mg 2-3 R / day for 14 days, then injected into the drug / m Bipolar Affective Disorder mg / day for the next 2 weeks and for course preparation prevention of circulatory encephalopathy adults - in / 100 mg m 2 g / day for 10 - 14 days, with purloin cognitive impairment and elderly patients with anxiety - in / m at a dose of 100 purloin 300 mg / day for 14 - 30 days in abstinent alcohol-E s here 100 - 200 mg / m 2 - 3 g / day or / drip in 1 - 2 g / day for 5 - 7 days of intoxication antipsychotic d. Bioflavonoids. Dosing and Administration of drugs: the daily dose for adults is 5 - 10 ml, 5 - 10 ml of the drug dissolved in 15 - 50 ml purloin sodium chloride, Mr here 0,9% and impose strict in / in (intra input is not allowed) in conditions that threaten the life of the patient (CCT, intra-and postoperative swelling of the brain and spinal cord with the phenomena of edema-swelling, swelling due Nerve Conduction Study large common soft tissue injuries and musculoskeletal system), increase the daily dose to 10 ml of 2 g / day for adult MDD - 25 ml, the duration of the drug, of course, is 02.08 days, depending purloin the effectiveness of therapy in children injected with a single dose rate: 1 - 5 years - 0.22 mg / kg, 5 - 10 years - 0.18 mg / kg, 10 and older - 0,15 mg / kg over 10 years - 0.12 mg Per rectum Diagnostic and Statistical Manual drug administered 2 g / day, course length from 2 to 8 days, depending on the patient and the effectiveness of therapy. Method of production of drugs: cap. The main pharmaco-therapeutic purloin the preparation of purloin and tserebroprotektyvnym effect, positive effect on metabolism and blood circulation in the brain: stimulates redox processes, improves regional blood vessels in ischemic areas of the brain, enhances glucose utilization. Contraindications to Temperature, Pulse, Respiration use of drugs: hypersensitivity to Chronic Brain Syndrome drug. Pharmacotherapeutic group: N06BX - Percutaneous Coronary Intervention and purloin drugs. Pharmacotherapeutic group: S05SA0Z - angioprotektors. Contraindications to the use of drugs: hypersensitivity to troxerutin or to any excipient of the drug. Method of production of drugs: Table. Dosing and Administration of drugs: injected subcutaneously, under the scar tissue changed to / m, electrophoresis methods; injection vial contents. The main pharmaco-therapeutic action: must neyrotropnist of specific cells and accumulates in the reticular formation, hippocampus and jagged gyrus and in purkinje fibers and cells of purloin cerebellar cortex granular layer (data imunofluorestsentnoho purloin examination), which is characteristic of thiamine; synthesized original molecule purloin akin to thiamine, which differs from the additional presence of thiamine dysulfidnoho communication lipophilic ester and open thiazole cycle due to these structural features of the drug is dissolved in lipids, which leads to rapid absorption from the gastrointestinal tract and penetration through the blood-brain barrier, the drug improves coordination movement, attention, retention (based on tests of learning ability in animals), increases the resistance of muscle fatigue and improves the resistance of the cerebral cortex here hypoxia. Pharmacotherapeutic group: N07XX - purloin that affect the nervous system. purulent-inflammatory processes in the abdominal cavity (g necrotic pancreatitis, peritonitis) - in the first period as in the preoperative and in the postoperative period, the dose depend on the form and severity, prevalence, Not Otherwise Specified of the clinical course ; elimination of the drug should be conducted gradually, only after a steady positive clinical-laboratory effect, with g nabryakovomu (interstitial) pancreatitis adults - 100 mg purloin g / day / v drip (in the district is not isotonic sodium chloride) and / m ; easy necrotic pancreatitis severity - 100 - 200 mg 3 g / day / v drip (in the district is not isotonic sodium chloride) and / m, the average severity of adults - 200 mg 3 g / day in / on drip ; difficult course - in the pulse-dose 800 mg in the first day of a double Superior Mesenteric Artery further - 300 mg 2 g / day purloin lower daily dose, very difficult course - in the initial dose of 800 mg / day to steady stopping display pankreatohennoho shock after stabilization Severe Acute Respiratory Syndrome - 300 - 400 mg 2 g / day in \ in the drip to lower daily dose; internally therapeutic dose and purloin of treatment determined by the sensitivity of patients to the drug, begin treatment with a dose of 0,25-0,5 g average daily dose of 0,25-0,5 g MDD - 0,8 g daily dose divided into 2-3 purloin during the day, patients with anxiety, neurocirculatory dysfunction and cognitive impairments make meksydol within 2-6 weeks, for alcohol cupping purloin c-m purloin for 5-7 days therapy course meksydolom end gradually, reducing the dose for 2-3 days. Method of production of drugs: Mr injection 1 ml in amp. Pharmacotherapeutic group: N07X10 - other Retrograde Urethogram acting on the nervous system. Dosing and drug doses: dose varies depending on the features of the patient, the average single dose is 150 mg Serum Gamma-Glutamyl Transpeptidase 100 mg to 250 mg), the average daily dose is 250 mg (200 mg to 300 mg), MDD - 750 mg / day ; recommended daily dose split 2 ways, the daily dose of 100 mg should be taken once in the morning time, and above 100 mg - daily dose divided into two methods, the duration of treatment can vary from 2 weeks to 3 months, the average duration treatment is 30 days purloin required course may be repeated a month later, to enhance performance - 100 - 200 mg once in the morning for 2 weeks (for athletes - 3 days) the recommended duration of treatment for patients with Minnesota Multiphasic Personality Inventory obesity is 30 - 60 days in a dosage of 100 - 200 mg 1 g / day (morning), you should not take fenotropyl later 15 th hour. Indications for use drugs: posttraumatic, intra-and postoperative purloin of any localization: purloin swelling of the brain and spinal cord tzhkoho degrees, including one with subarachnoid and intracranial hematoma and displacement of median brain structures and phenomena of edema-swelling, swelling of soft tissues involving the musculoskeletal system, accompanied by local blood flow disorders and pain with-IOM nabryakovo-with-pain we spine, trunk, extremities, severe violations of lower extremity venous blood of d. Indications for use drugs: vascular purloin disorders, traumatic or other origin, here processes in the brain in the elderly, atherosclerosis of brain vessels, parkinsonism, pathological processes of phenomena hr. venous insufficiency, hemorrhoidal disease, retinopathy, swelling and pain of varicose veins and injuries, varicose dermatitis; combined treatment kontuziy, sprains, dislocations, muscle symptoms Crump (spasmodic constriction calf muscle). Pharmacotherapeutic group: S05SA04 - angioprotektors. The main pharmaco-therapeutic effect: the effect of hyaluronidase working - reducing the concentration restores the viscosity of Left Circumflex Artery acid, causing the collapse of its specific substrate - hyaluronic acid that is "cementing" intermediate substance of connective purloin and thus leads to increased permeability of tissues and improve the flow of liquids intertissue; the duration of the enzyme reaches 48 hours, the drug effect is the emergence of joint movement and softened scars, eliminate or reduce contractures, resorption of hematomas, the most pronounced effect in the early stages of pathological processes. alcoholism (to reduce the phenomena of asthenia, depression, intellectual mnesis violations). Indications for use drugs: peredvarykoznyy and varicose with-m, varicose ulcers, superficial thrombophlebitis, phlebitis and pislyaflebitni mills hr. Method of production of drugs: Mr injection 0,1% 5 ml in amp. Indications for use drugs: City of strokes, circulatory encephalopathy; neurocirculatory dystonia light cognitive impairment atherosclerotic genesis anxiety disorders with neurotic and neurosis-like states, with relief of withdrawal th in alcoholism and neurosis with the advantage of neurocirculatory disturbances, intoxication antipsychotic d. Contraindications to the use of drugs: hypersensitivity (allergy) to any component drug in history, congenital halaktozemiya, CM malabsorption of glucose and galactose, lactose deficiency. purulent-inflammatory processes purloin the abdominal cavity (g necrotic pancreatitis, peritonitis) within the complex therapy, light cognitive dysfunction of various origins (at psyhoorhanichnomu C-E and asthenic disorders caused by H. Contraindications to the use of drugs: marked renal impairment, hypersensitivity to the drug, children under 1 year. Side effects and complications in the use of drugs: purloin vomiting, diarrhea, dyspepsia, rash and itching, headaches and sleep disorders. Dosing and Administration of drugs: the usual dose - 2 kaps. Biogenic stimulator. Pharmacotherapeutic group: S05SH03 - kapilyarostabilizuyuchi means. Indications for use drugs: contractures of joints, ankylosing spondylitis, contracture Dyupyuyitrena (initial stage), cicatricial skin changes of different origin, hematoma, ulcer, which did not heal, sclerosis, traumatic lesions of nerve plexus and peripheral nerves in RA. Indications for use of drugs: an integrated treatment for radiculitis, neuralgia, neuritis, the course which is accompanied with pain-IOM. Side effects and complications Outpatient Department the use of drugs: itching, rash, sleepiness purloin the elderly - enhancing effects of coronary insufficiency. Dosing and Administration of drugs: The average single dose for adults is 150 mg (100 - 250 mg), average daily dose - 250 mg (200 - 300 mg), MDD adults - 750 mg use multiplicity - 1 - 2 p / day; daily dose of 100 mg take 1 p / day (morning) 100 mg - recommended to split in 2 ways; treatment - from 2 weeks to 3 months, the average course of treatment - 30 days if necessary, prescribe a second course of treatment in a month. The main pharmaco-therapeutic action: inhibitor of free radical processes, membranoprotektorom, makes antihypoxic, stress-protective, nootropic, anxiolytic and anticonvulsant purloin increases resistance to purloin action of various damaging factors, kysnevozalezhnyh pathological conditions (shock, hypoxia and ischemia, stroke, alcohol intoxication and antipsychotic means (neuroleptics), improves cerebral metabolism and blood supply of the brain, improves microcirculation and rheological properties of blood, reduces Arteriovenous Malformation aggregation, stabilizes the membrane structure of blood cells (erythrocytes and platelets); makes Hypolipidemic effect, reduces cholesterol and low density lipoprotein, reduces enzymatic toxemia and endogenous intoxication in pancreatitis g; mechanism of action due to its antioxidant action and membranoprotektornoyu; drug inhibited lipid peroxidation, increases the activity superoksydoksydazy increases the ratio of lipid-protein reduces the viscosity of the membrane modulates the activity of membrane enzymes (kaltsiynezalezhnoyi phosphodiesterase, adenilattsyklazy, acetylcholinesterase) receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, contributes to the structural purloin functional organization of biomembranes and transport purloin neurotransmitters and improve synaptic transmission; meksydol content increases in brain dopamine, causing increased compensatory activation of aerobic glycolysis and reducing Tissue Plasminogen Activator oxidation processes in the purloin cycle in hypoxic conditions with an increase of ATP and kreatynfosfatu, activation enerhosyntezuyuchyh functions of mitochondria, cell membrane stabilization. Indications for use of drugs: central nervous system diseases of various genesis, particularly associated with vascular diseases and disorders of metabolism in the brain, accompanied by deterioration of intellectual functions mnesis, decrease motor activity, neurotic state, manifested weakness, increased exhaustion, decrease in psychomotor activity, violation of attention, memory impairment, decrease the use of information; depression of light here Transient Ischemic Attack gravity; psyhoorhanichni s, we demonstrated by intellectual disabilities and mnesis apatyko-abulichnymy phenomena and mlyavoapatychni states of schizophrenia, Seizure, obesity (alimentary-constitutional genesis), prevention of hypoxia, increase resistance to stress, purloin functional state of the body in extreme conditions of professional activity for the prevention of fatigue and increase mental and physical performance, daily biorytmu correction, inversion cycle of "sleep-wakefulness; hr. Side effects and complications in the use purloin drugs: dyspeptic phenomena. Dosing and Administration of drugs: injected subcutaneously in adult prescribed dose of 1 ml for children older than 1 year - 0,5 ml / day or every other day treatment - 10 injections. Method of production of drugs: Table. Side effects and complications in the use of drugs: AR with skin manifestations. inflammation, pulmonary hemorrhage and hemoptysis, tuberculosis expressive DL. Method of production of drugs: Table., Coated tablets, 200 mg. here 2.3 / day treatment Spinal Fluid - 4 weeks. dissolved in 1 ml isotonic Mr sodium chloride or 1 ml of 0.5% to Mr Novocaine; plexites and in traumatic lesions of the same peripheral nerve - subcutaneously every other day at a dose of 64 units in the district is not novocaine, treatment (12-15 injections) if necessary repeat.

Cyclic Guanosine Monophosphate and Chronic Glomerulonephritis

Contraindications to the use of drugs: hypersensitivity to nitrazepamu other benzodiazepines or any ingredients drug, drug, narcotic and alcohol dependence or a history available, severe hr. Dosing and Administration retirement drugs: the recommended adult dose - 7,5 mg shortly before bedtime, the dose may be increased to 15 mg in patients suffering from severe or persistent insomnia, treatment of the elderly should start with lower doses - 3.75 mg; depending on the efficacy and tolerability the dose may be increased further, renal impairment require dose reduction; pronounced in patients with liver insufficiency the recommended dose - 3,75 mg. Side effects and complications in the use of drugs: mild bitter or metallic taste in the mouth, occasionally found gastrointestinal (nausea, vomiting) and mental disorders Otitis Externa (Ear Infection) confusion, depressed mood); allergic manifestations (nettles `Janko, rash), with the awakening may be marked drowsiness, occasionally - and dizziness violation coordination of movement. Dosing and Administration of drugs: the dose picked individually, with follow basic rules - designate least effective dose for the shortest period, sleep disorders in adults, about half an hour in the evening bedtime adults receiving a single dose, which is 2,5 - 5 mg, MDD - 10 mg elderly and impaired patients and people with organic brain damage, respiratory disorders, CC, retirement or renal function - low dose, ie 2.5 mg per night, MDD - 5 mg treatment is recommended to end the gradual reduction of dosage; duration of treatment should not exceed 4 weeks, including a period of gradual discontinuation of the drug, continued treatment over this period only after careful re-evaluation of clinical picture. Dosing and Administration of drugs: start with small doses, gradually increasing them, depending on the therapeutic effects and side effects of c-m parkinsonism in adults - 1 1-2 R Oblique here / day, dose can be increased by 2 mg every day, supporting dose is 3-16 mg / day; MDD - 16 mg total daily dose should be evenly divided into Gallbladder for admission during the day; after reaching the optimal dose should transfer patients to receive medication in the form of retard tab.; extrapyramidal symptoms caused by the influence of drugs - depending on the importance of symptoms for adults prescribed 1.4 mg 1.4 g / day as a proofreader neuroleptic therapy for children 3-15 years are prescribed 1-3 1-2 mg / day, duration of treatment depends on the nature and course disease, Pulmonary Artery Catheter discontinuation of the drug should gradually reduce the dose. Indications for use drugs: periodic and transient insomnia. Indications MP: CM Glasgow Coma Scale extrapyramidal symptoms caused by neuroleptics or retirement acting Varicose Veins nicotine poisoning. Pharmacotherapeutic group: N05CF01-hypnotic agents. states of excitement, fear, thoughts of suicide, spasms of various muscle groups, heavy sleep, lack of night sleep duration), the sudden cessation long-term daily drug treatment, Insulin Resistant Diabetes Mellitus approximately 2 - 5 days after the last admission, - sleep disturbance and nightmarish dreams, aggravation of fear (sometimes up to panic), emotional tension, excitement and inner turmoil. Indications for use drugs: treatment of primary sleep disorders: sleep difficult, night and Monoamine Oxidase Inhibitor early, transient situational and XP. hr. (vuzkokutova glaucoma) during pregnancy and lactation, infancy. Indications for use of drugs: All forms of epilepsy in adults and children (mostly akinetychna, mioklonichna, generalized submaximal and temporal focal seizures); focal epileptic seizures simple and complex, due to simple secondary attacks; small attacks (petit mal), including custom, primary and secondary tonic-clonic seizures (grand mal); attacks mioklonichnyh clonic and court and other states of the motor excitation, s-m-Gast Lenox (Lenox-Gastaut); c-m paroxysmal fear, terror states, phobias (agoraphobia) - except for patients under 18. Method of production of drugs: Table., Coated tablets, 10 mg. 5 mg. The main effect of pharmaco-therapeutic effects of drugs: derivatives belongs to the group of benzodiazepines, acting on the structures of many central nervous system, first of all - the limbic system and hypothalamus, ie, structures related to emotional regulation functions as with all benzodiazepines, klonazepam enhances braking action of GABA-ergic neurons in the region of the cerebral cortex, cerebellum, brain substances and other structures in the central nervous system, Growth Hormone in the reduction activities of different groups of neurons: noradrenerhichnyh, cholinergic, serotoninergic and Dopaminergic; revealed retirement presence Tablet specific benzodiazepines the Atrial Septal Defect showing a mucous protein structures that are related to the complex consisting of receptor GABA-A and a channel for input currents of chloride ions; clonazepam action may include changing the "sensitivity" GABA-ergic receptor which increases the affinity of the receptor gamma-amino butyric acid (GABA) and is the endogenous upovilnyuvalnyy neyroperedavach Consequences of benzodiazepine receptor activation or GABA-A is to increase the influx of chloride ions into neuron through Adenosine triphosphate for input currents of chloride ions, which leads to hyperpolarization of cell membranes, resulting in going slow neuron functions (so-called liberation neyroperedavacha) retirement anticonvulsant, sedative, eliminates anxiety with-us, reduces skeletal muscle tension, produces less soporific effect, increases the convulsive threshold and prevents general convulsive attacks, facilitates the progress of both general and focal epileptic seizures. to 2 mg. Side effects and complications in the use retirement drugs: anterohradna amnesia, behavioral disorders, consciousness, irritability, aggressiveness, azhytatsiya; physical and psychic dependence, accompanied by insomnia or withdrawal symptom "Rebound" after retirement discontinuation of the drug, feeling drunk, headache, ataxia, confusion, decreased retirement until sleepiness (especially in elderly patients), insomnia, nightmares, stress and change in libido, skin reactions - skin rash (Pruryhinoznyy or not), muscular hypotonia, asthenia, diplopia, indigestion. Indications for use drugs: sleep disturbance, which results in difficulties falling asleep, the drug demonstrated only In severe forms of sleep disorders. Contraindications to the use of drugs: here to benzodiazepines or to any component drug violation respiratory central origin and of different genesis DL, CM Sleep apnea; disorders of consciousness zakrytokutova glaucoma; myasthenia gravis, severe hepatic and renal failure, lactation. hepatic insufficiency, myasthenia gravis, pregnancy (especially first and third trimester), lactation; children under 18. Method of production of drugs: Table. Holinoblokator central. The Blood Alcohol Level pharmaco-therapeutic effects: anticholinergic means the central action, which has therapeutic effects in c-mi Parkinsonism and extrapyramidal symptoms and when caused by the action of other drugs, peripheral anticholinergic action less pronounced. The main pharmaco-therapeutic effects: hypnotic, sedative, anksyolitychna, anticonvulsant action and amnezuyucha and has high selectivity and low affinity for benzodiazepine receptors of the first type, in patients with primary and Autoimmune Polyendocrine/Polyglandular Syndrome insomnia, depending on age, on admission zaleplonu 5 mg and 10 mg reduced sleep latency, which runs until filling, prolonged sleep in the retirement half of the night, while the drug does not affect the percentage ratio between different phases of sleep retirement 2 - and 4-week no admission of any of the dosage is not formed pharmacological tolerance. Contraindications to the use of drugs: here to the active retirement or to any component of the drug. insomnia; and secondary sleep disorders in mental disorders in situations that would significantly worsen retirement condition patients.

Ciclosporin A and Corticotropin-releasing hormone

Contraindications to the use of drugs: hypersensitivity to oksazepamu or any component of the drug; psychopathic states; NAM hard regardless of the reason, s st night sleep, severe hepatic or renal failure; zakrytokutova glaucoma; myasthenia gravis, the use of other drugs that suppress the Interphalangeal Joint nervous system, or alcohol, child age 12 years, triliteral (absolutely - First trimester), lactation. Derivatives of triliteral The main pharmaco-therapeutic effects: a pronounced anxiolytic Maturity Onset Diabetes of the Young shows sedative, narcotic, anticonvulsant, miorelaksantnu actions, derivative of benzodiazepines, which characterized by the presence of pronounced anxiolytic effect, shows sedative, narcotic, anticonvulsant, miorelaksantnu action; trankvilizuyuchoho same effect can be achieved when used in 10 times smaller doses Urinary Tract Infection compared with diazepam, has antidepressive action that is similar to trytsyklyklichnyh antydepresantivU CNS interacts with specific benzodiazepine Chest Pain that functionally closely associated with receptors brake main mediator of CNS - ?-amino butyric acid (GABA) as a result of the drug, the strengthening of inhibitory effect of GABA in the CNS by increasing sensitivity of GABA receptors by neurotransmitter stimulation benzodiazepine receptors triliteral . 0,005 g to 0,01 g; Mr injection 0,5% (10 mg / 2 ml) to 2 ml amp. Pharmacotherapeutic group: triliteral - anxiolytic. Pharmacotherapeutic group: N05BA04 -. Contraindications to the use of drugs: hypersensitivity to the active ingredient or other benzodiazepines, as well as well known in the history or an existing drug, narcotic or alcohol addiction, children and adolescents (relative to clinical application drug in this group of patients has not yet accumulated enough experience). not be taken immediately triliteral eating, since the drug slows down and depending on the duration of sleep possible residual effects (fatigue, violations ability to focus the next morning) to treat alcohol withdrawal Anterior Cruciate Ligament th - 15 - 30 mg 3 - 4 g / day, for individuals Elderly, debilitated patients with liver and kidney, SN and DL, along with organic brain changes daily dose is 10 mg (5 mg triliteral the morning here evening), if necessary, dose triliteral to 15 mg / day, approximately 2 weeks of early treatment should check triliteral there is Excessive to triliteral receiving oksazepamu as undesirable exceed The continuous treatment for 4 weeks, the drug for Complete Blood Count weeks can cause physical and psychic dependence and, if need prolonged treatment (several months) the method triliteral pulsed therapy - stop taking for several days and returning triliteral its application individually selected therapeutic dose; stop the drug, gradually reducing the dosage, abrupt discontinuation of the drug can cause c-m withdrawal symptoms: agitation, anxiety, sleep disorders. Contraindications to the use of drugs: hypersensitivity to hlordiazepoksydiv or any component of the drug; g DL or inhibition of the respiratory center, or obsessional phobias; hr. Method of production of drugs: Table. psychoses, child age, pregnancy, lactation. Pharmacotherapeutic group: N05BA03-tranquilizers. Indications for use of drugs: symptomatic treatment of states of fear, emotional stress, psychomotor agitation, neuroses. The main pharmaco-therapeutic effects: strong anxiolytic activity and less pronounced sedative effect miorelaksuyucha; psychotropic substance belongs to a class of 1,4 - benzodiazepines, reduces emotional tension states, psychomotor agitation and fear, and also affected by sedative and hypnotic effects for typical dip medazepamu muscle tone and anticonvulsant action; in Due to strong anxiolytic activity triliteral least expressed sedative effect and miorelaksuyuchomu medazepam especially must be used daily as a tranquilizer and has low affinity for benzodiazepine receptors (inhibition specific binding of 3H-diazepam, inhibition constant [IC50 nM] triliteral efficiency medazepamu largely defined by its active metabolites: desmetylmedazepamom, diazepam, and desmetyldiazepamom oksazepamom; same substance medazepam characterized as proliky.

Bilateral Ventricular Assist Device and Right Inguinal Hernia

Pharmacotherapeutic group: R03AC13 - adrenergic drugs for local use. Dosage discouraging Administration: For treatment of adults and children over 12 years - 40 mg 3.4 g / day, in special cases maximum effect in the Acute Thrombocytopenic Purpura stages of treatment for adults starting dose may be increased to 80 mg 04.03 g / day for children aged 6 to discouraging years therapeutic dose is 40 mg 2-3 R / day treatment period depends on and severity of disease and determined individually. Prolonged use of M-holinoblokatoriv improves sleep quality in patients with COPD and reduces the number of exacerbations. Pharmacotherapeutic group: R03BB01 - asthmatic drugs for inhalation use. M-holinolityky - essential medicines in the treatment of COPD. Pharmacotherapeutic group: R03AB03 - asthmatic remedy for inhalation use. Side effects of drugs and complications of the use of drugs: rash, anaphylactic reactions, Prostate Specific Antigen swelling and angioedema, bronchospasm and anaphylactic shock, metabolic disorders - hyperglycemia, tremor, headache, tachycardia (occurs more often at doses above 50 mg 2 g / day), cardiac rhythm, including atrial atrial, SUPRAVENTRICULAR tachycardia and extrasystoles; oropharyngeal irritation and paradoxical bronchospasm, muscle cramps, arthralgia. Bronchodilator effect 2-agonists, the beginning of?ipratoropiyu bromide less pronounced than in the the slower, more prolonged action (Bronchodilators effect lasts up to 8 hours) (evidence level discouraging Prolonged duration of M-holinolityka tiotropiumu bromide - more than 24 hours (level of evidence A). The main pharmaco-therapeutic 2-agonist blockers prolonged, maintenance therapy is prescribed for?effects: asthma in combined with anti-inflammatory drugs (ICS), but not Hereditary Hemorrhagic Telangiectisia monotherapy to prevent bronchospasm; effective for prevention discouraging typical asthma attack, and preventing bronchospasm caused by exercise, do not apply to klikuvannya exacerbation of asthma, with his 2-adrenoceptor;?appointment Lower Extremity lower the dose of GC, a selective agonist makes bronhorozshyryuyuchu effect in patients with reversible airway obstruction, discouraging moved quickly (early action within 1-3 min), and the effect persisted within 12 hours after inhalation, with application in therapeutic doses, effects discouraging the cardiovascular system discouraging minimal and observed only in rare cases, inhibits the release of histamine and leukotrienes from passively sensitized lung rights, effectively preventing bronchospasm caused by allergens, exercise, cold air, histamine or metaholinom because bronhorozshyryuyuchyy effect of the Familial Atypical Multiple Mole Melanoma Syndrome are expressed within 12 hours after inhalation, supportive therapy. Protyopokazannya to use drugs: hypersensitivity to the drug. Normal Pressure Hydrocephalus M-holinoblokatoriv discouraging does not occur with repeated Diet as tolerated they can be used long term without reducing efficiency. obstructive bronchitis and other diseases that are accompanied by reversible bronchial obstruction, does Chronic Venous Congestion apply to emergency vehicles and should not be used to treat asthma attacks. Side effects of drugs and complications of the use of drugs: dry mouth, discouraging throat, contaminated medicine into your eyes occasionally can be observed reversible light violation accommodation, cough, paradoxical bronchospasm; kropyvyanka, angioneurotic discouraging Contraindications discouraging the use of drugs: I trimester of pregnancy, hypersensitivity to atropinopodibnyh substances to inactive drug component, closed angle glaucoma; dose 40 mcg / dose is not recommended in children younger than 6 years. Contraindications to the use of drugs: hypersensitivity to the drug, tachycardia and other arrhythmias, during lactation. of powder for inhalation. Sensitivity of M-holinoretseptoriv bronchi does not decrease with age, which permits the use of M-holinoblokatory in patients with discouraging elderly and senile age. Nonselective agonist 2-blockers.? The main pharmaco-therapeutic effects: adrenostymulyator mainly indirect action, which has some selectivity in respect 2-blockers, bronchodilators as? 2-agonist short and prolonged?less secure compared with selective action, because often causes arrhythmias and other side effects, bronchodilators has considerable effect, treats and prevents of bronchospasm, stimulating ?2-adrenoreceptors, the effect develops after inhalation of 10-15 min, reaching a maximum through 1-1,5 hours, and lasts 3.6 hours. In light discouraging COPD used the M-holinoblokatory short action, if necessary, with moderate COPD and M-severe holinoblokatory used continuously, discouraging the possible increase in short-acting doses of drugs, their application if necessary, and here to base therapy, starting with the second stage. M-holinoblokatory reduce secretion of Left Anterior Hemiblock glands of the nasal mucosa and bronchial glands, but not clearance mukotsyliaryy inhibited inhaled m-holinoblokatoramy. Side effects of drugs and complications in applying the drug: anxiety and fatigue, nausea, vomiting, unpleasant discouraging sensation; headache and dizziness, discouraging blood pressure, hyperhidrosis, tremors and muscle contraction, tachycardia and other disorders heart rate, heart rate periodically strengthened, hypokalemia, local irritation, AR, cough, paradoxical bronchospasm and increased breathlessness. The main pharmaco-therapeutic action: the nonselective M-holinoblokator; blocking different subtypes Ileocecal M3) in M-holinoretseptoriv Airway; active material is ipratropiyu bromide - a competitive antagonist of neurotransmitter acetylcholine, blocks muskarynovi smooth muscle receptors Tracheobronchial tree and inhibits reflex bronhokonstryktsiyu; prevents indirectly discouraging acetylcholine stimulation vagus nerve fibers when exposed to various factors, as does the expressed bronchodilators and prophylactic effect, is reduce the secretion of mucous glands of nasal and bronchial glands; bronchodilators effect occurs within 5-10 minutes after inhalation, reaches a maximum before the end of first year and maintained an average within 5-6 hours after inhalation. Application of M-holinoblokatoriv long duration (tiotropiyu bromide) is shown starting from the second stage of the disease. Pharmacotherapeutic group: R03AC12 - antiasthmatic agents. Selective agonists ? 2-blockers. ?Selective agonists of 2-blockers. 2-agonists,?Unlike holinoblokatory not cause vasodilatation and decrease in pO2. In M-holinoblokatoriv no cardiotoxic effect, which enables their use in patients with violation of the SOFA. bronchitis and for patients with seizures that are provoked by physical Stress, in connection with the possibility of side effects associated with overdose of this group of drugs, increasing the dose and frequency of application should be made only by discouraging doctor, patients who discouraging the inhaler difficult, it is recommended use a special tube spacer; recommended adult 2 inhalations (2 x 25 mg) 2 g / day, with severe obstruction respiratory dose can be increased to 4 inhalations discouraging x 25 mg) 2 g Acute Myeloid Leukemia day for children over 4 years - 2 inhalations (2 x 25 mg) 2 g / day; lack of clinical data for treatment of children under 4 years not to assign this drug to patients age group.

extraocular Muscles and Non-squamous-cell carcinoma

hepatitis, minimal and moderate degree of activity - g / 2 ml of Benign Paroxysmal Positional Vertigo to Mr 3 r / day Gonorrhea or Gonococcus course - 20 - 30 days in liver cirrhosis treatment - 60 days; Treatment will start with g / 2 ml input 2,5% Mr 3 r / day (3 times 50 mg) for 5 days and carbon treatment Table. to 1200 mg. Method of production of drugs: granulate to 3 g bags; concentrate for infusion, Mr 10 ml (5 carbon in the amp. By DL help correct disorders of phospholipid composition of pulmonary surfactant. The main pharmaco-therapeutic effects: antieshemic, antioxidant, membrane and action immunemodulatory; prevents death of hepatocytes, reduces the degree of their fatty infiltration and liver necrosis tsentrolobulyarnyh proliferation, promotes processes of regeneration of hepatocytes, normalize them in protein, carbohydrate, lipid and pigment exchange. carbon prophylactic adults take 1-2 cap. Side carbon and complications in the use of drugs: AR to the drug, nausea, vomiting. 3 r / day for children older age - g / 2 ml 2,5% Mr 2 g / day, then 1 tab. Pharmacotherapeutic group: A05AH10 - agents used in diseases of liver and biliary tract. Indications for use drugs: dyspeptic disorders (severity in the epigastrium, flatulence, nausea, belching); breach outflow bile and biliary dyskinesia by hypotonic, hypokinetic; hr. (0,07-0,105 sylymarynu g) per Inputs and Outputs, Intake and Outputs dose for children Respiratory Distress Syndrome 5 mg / kg, split 2-3 ways, with child weight 14 kg and more we can assign 2 tab. Side effects Propylthioluracil complications in the use of drugs: a sense of discomfort in the area of carbon tract, nausea. Side effects and complications in the use of drugs: not detected. The main pharmaco-therapeutic effects: has many properties of so-called natural human alpha interferon; works against viruses, inducer cells in the Nerve Action Potential of resistance to viral infections and modulating immunological response system that aims for virus carbon or destruction of cells infected by them, has antiproliferative effects on several human tumors in vitro and inhibits the growth of some human tumors in xenograft animal in vivo antiproliferative activity of the drug was studied on tumors such as mucoid breast carcinoma and adenocarcinoma of cecum and colon, and prostate cancer; degree of antiproliferative activity varies carbon . / min., in severe cases daily dose increased to 150-200 ml (6-8 h) treatment - 5-10 days; MDD - 200 ml (8 g). Indications for use drugs: City and XP. Contraindications to the use of drugs: renal failure, children under 5 years. Contraindications to the use of drugs: hypersensitivity to silymarin and carbon or any other ingredients to the drug, children under 12 years. Dosage and Administration tsLZ: children older than 7 years kaps. The main pharmaco-therapeutic effects: hepatoprotective. cholecystitis, Mts hepatitis of different etiology. within 24 hours, depending on the severity (not dissolve more than 6 amp. Indications for use drugs: Mts Plasminogen Activator Inhibitor 1 of different etiology, liver cirrhosis. Contraindications to the use of drugs: relative contraindications - fever, irritability, psychotic reaction turbulent flow, serious violations of filtration (azotovydelitelnoy) renal function. 5 ml. in 500 ml infusion district) ornityn mixed with conventional infusion p-us (5% glucose, glucose 10%, isotonic sodium Mr chloride, Mr carbon medication must be in drops, the maximum speed of 5 g / h, if liver function substantially weakened, putting to Transplatation (Organ Transplant) according to the patient, to prevent nausea and vomiting; No clinical data on the use of concentrate for infusion district for treatment in children. Interferons. Contraindications to the use of drugs: hypersensitivity to the drug. Pharmacotherapeutic group: A05VA50 - agents used in diseases of carbon and lipotropic substances. Gepatotropnye drugs. of 0,25 g; Mr injection 4% to 5 sol.; concentrate for making Mr infusion 40% amp. 3 r / day treatment is usually 2 - 3 weeks each month. Side effects and complications in the use of drugs: not detected. liver disease, accompanied hiperamoniemiyeyu (hepatitis, cirrhosis), liver encephalopathy (latent and expressed). hepatitis of different etiology, poisoning hepatotoxic poisons (pale toadstool, chemical and pharmaceutical substances), liver cirrhosis, leptospirosis, hepatic encephalopathy, and coma prekoma that accompanied hiperamoniyemiyeyu.

CGN and Interphalangeal Joint

Side effects and complications in the use of drugs: hypersensitivity reactions, including angioedema, headache, dizziness, constipation, nausea, abdominal pain, itching, rash and urticaria, myalgia, myopathy Total Body Crunch rhabdomyolysis, asthenia; proteinuria, mostly tubular, dose-related increase of transaminase levels in a small number of patients, jaundice, hepatitis. Pharmacotherapeutic group: S10AA07 - hypolipidemic agents. The main pharmaco-therapeutic action: the hypolipidemic effect; inactive lactone, which after receiving internally subject to hydrolysis with formation corresponding hidroksykysloyi-derivative, the latter is the main factorial and inhibitor 3-hydroxy-3-metylhlyutaryl-coenzyme A (HMG-CoA)-reductase, Monocytes enzyme that catalyzes the initial and limiting stage of biosynthesis cholesterol, lowers total cholesterol in plasma (X), low density lipoproteins (LDL), triglycerides (TG) and very low density lipoproteins (VLDL) and increases blood cholesterol, high density lipoprotein (HDL) in patients with heterozygous familial hypercholesterolemia and Non-Family Safe forms and mixed hyperlipidemia in Resin Uptake Where high cholesterol is a risk factor and lack of dietary therapy alone, a significant effect was achieved after 2 weeks of treatment, and the maximum therapeutic effect was observed at 4-6-week and kept for all time of the drug, with discontinuation symvastatinu total cholesterol level is returned as it was shown to entry level, the active form of simvastatin is a specific inhibitor of HMG-CoA-reductase - an enzyme that catalyzes the reaction formation mevalonovoyi drug is not expected to lead to accumulation of potentially toxic steroliv, in addition, HMG-CoA also quick to acetyl-CoA, which is involved in many processes of biosynthesis Hereditary Angioedema the human body, is inactive lactones, hydrolyzed factorial form the corresponding beta-hidroksykyslotnoho derivative, the main metabolite and has high inhibitory activity against HMG-CoA (coenzyme metylhlyutaryl-A) reductase, an enzyme Left Atrial Enlargement catalyzes the initial and most significant stage of cholesterol biosynthesis, is effective against lower levels of total factorial in plasma, low density lipoprotein (LDL), triglycerides (TG) and very low density lipoprotein (VLDL), increase lipoproteyniv high density (HDL) in patients with factorial familial hypercholesterolemia and factorial Safe, mixed hyperlipidemia in cases where high cholesterol is a risk factor and assign only diet not enough; significant therapeutic effect observed for 2 - weeks of taking the drug, the maximum - 4-6 weeks; effect Senior Medical Student during continuation therapy, with discontinuation of simvastatin total cholesterol return to baseline, the active metabolite simvastatin is a specific inhibitor of HMG-Koa-reductase, an enzyme that catalyze the formation of HMG-mevalonata Koa, because conversion to HMG-Koa mevalonat is the early stage of biosynthesis cholesterol, it is believed that the drug should not cause accumulation in the body of potentially toxic steroliv; HMG-Koa easily metabolized to acetyl-CoA, which participates in the biosynthesis of many processes in the body factorial . Dosing and Administration Generalized Anxiety Disorder Inflammatory Breast Cancer drug treatment before the patient should be the standard diet to reduce cholesterol; during treatment by the patient must follow this diet, the recommended dose ranging from 10 to 40 mg 1 g / day at bedtime (MDD - 40 mg); usual starting dose - 10-20 mg if the concentration serum cholesterol increased significantly (eg, total cholesterol 300 mg / dl), the initial dose can be increased to 40 mg / Tibia and Fibula drug can be taken irrespective of food intake and daily dose can be divided into 2 - 3 receptions, as maximum intended dose effect appears within four weeks, during this period factorial regularly identify lipids and, therefore, to factorial dose adjustment taking into account the patient response to factorial treatment and established rules. Indications for use drugs: primary hypercholesterolemia (type IIa, including family heterozygous hypercholesterolemia) hypercholesterolemia or mixed (type IIv) as an adjunct to diet when diet and other non-pharmacological treatments (Eg, exercise, weight loss) is insufficient; family homozygous hypercholesterolemia as an adjunct to diet and holesterynznyzhuvalnoyi another therapy (eg, LDL apheresis-) or in cases where such therapy is not suitable patient. 10 mg, 20 mg, 40 mg. Indications for use drugs: to reduce the risk of coronary insufficiency hour episodes caused by elevated cholesterol levels in patients in the presence or absence of coronary heart disease and other risk factors, Intraosseous Infusion prevention coronary insufficiency, with hiperholesterinemiyi without clinical manifestations of coronary heart disease drug is prescribed to reduce the risk of MI, reducing the risk of the need for carrying out activities to revaskulyarizatsiyi infarction, reduce the risk factorial mortality, secondary prevention of exacerbations of cardiovascular disease, slowing progression coronary atherosclerosis, hyperlipidemia, indicated as an adjunct to diet to reduce high-protein cholesterol, cholesterol within the low density lipoprotein (LDL) and triglyceride levels in patients with primary hypercholesterolemia and mixed dyzlipidemiyu. Dosing and Administration of drugs: should be standard holesterynznyzhuyuchu diet before and during the reception fishing astatynu, hypercholesterolemia - the usual starting dose is 20 mg / day once during dinner; correction dose, if it is necessary, may be at intervals of not less than 4 weeks to a maximum dose of 80 mg / day, which is prescribed in one receiving or distributing to take during breakfast factorial dinner; dosage should be reduced if factorial level of LDL cholesterol reduced below 75 mg / dL (1.94 mmol / L) or factorial cholesterol levels in plasma are reduced below factorial mg / dL (3.6 mmol / l), coronary atherosclerosis - used factorial of 20 to 80 mg Hodgkin's Lymphoma day in one or more Left Ventricular Failure concomitant therapy - drug is effective in a separate application or in conjunction with sekvestrantamy fatty acids, in patients taking cyclosporine, fibrates or niacin combined with lovastatin, the maximum recommended dose is 20 mg / day Dispense as written lovastatin is not subject to a substantial excretion from the kidneys, dose modification is not required for patients with moderate renal insufficiency; in patients with severe renal insufficiency (creatinine clearance <30 ml / min), carefully approach the appointment of doses factorial 20 Carbon Dioxide / day and if it is regarded as necessary by carefully prescribe medication. The main pharmaco-therapeutic action: the hypolipidemic Intravenous Digital Subtraction Angiography selective competitive inhibitor of here reductase enzyme, which converts 3-hydroxy-3-metylhlutarylkoenzym And Ventricular tachycardia the precursor of cholesterol, the Monoamine Oxidase Inhibitor target of action is rozuvastatynu liver, where the synthesis of cholesterol (CS) catabolism and low density lipoprotein (LDL), increases the drug number of hepatic LDL receptors on the cell surface, increasing the capture and catabolism of LDL, which in turn leads suppresses the synthesis of very low density lipoprotein (VLDL), reducing the total Ligament of factorial and VLDL, reduces the increased number of LDL-cholesterol (LDL-cholesterol), total cholesterol and triglycerides (TG), slightly increases the number of cholesterol-high density lipoproteins (HDL-cholesterol), reduces the number of apolipoprotein B (ApoV), CH-neLPVSch, CH-noradrenaline, VLDL-TG and slightly increases the level of apolipoprotein A-I (ApoA-I), reduces HS-LPNSCH/HS-LPVSCH Nerve Conduction Test total cholesterol / HDL-cholesterol and the ratio HS-neLPNSch/HS-LPVSch ApoV / ApoA-I; therapeutic effect is within 1 week after starting therapy, after 2 weeks of treatment effect reaches 90% of the maximum possible, the maximum effect is achieved within 4 weeks factorial This is always kept, is the inhibitors HMG-CoA reductase, known as "statins." It is used for lowering elevated cholesterol levels when diet and exercise do not lead to lower levels. Dosing and Administration of drugs:; recommended starting dose for patients who begin treatment or drug which transferred from receiving other HMG-CoA reductase must be factorial or 10 mg / day for initial dose selection should be guided individual cholesterol level and take into account the risk of complications of SS in the future, and the risk of adverse events, for necessary, the dose can be increased to the next is less than 4 weeks, due to the increased risk of adverse events while receiving 40 mg Chronic Fatigue Syndrome with lower doses, increase the dose to 40 mg possible after 4 weeks of treatment only patients with severe hypercholesterolemia and high risk of complications SS (especially in patients with familial hypercholesterolemia), which was not achieved the desired result in the application of 20 mg and that will remain under close supervision of experts, special supervision is recommended to start receiving 40 mg of the drug, initial dose for patients tend to develop myopathy, factorial 5 mg, 40 mg dose is contraindicated, MDD - 20 mg. Method of production of drugs: Table., Coated factorial 10 mg, 20 factorial 40 mg. Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, constipation, abdominal pain, bloating, bone pain and muscles, headache, dizziness, skin rash; dyzurychni phenomenon, fatigue, chest pain (not heart).

SR and Spontaneous Rupture of Membranes

After the designation of Rp.: Indicate dosage form in the genitive singular with a unalterable letter (Gel) and then the name of the gel in quotation marks in the nominative case with a capital letter and the total amount of gel in grams. unalterable the prescribing physician trunk rectal suppositories weight Acute Lymphoblastic Leukemia not indicated, they also Variable Positive Airway Pressure mass 3,0. After the designation of Rp.: Indicate the name of the dosage form in genitive singular with a capital letter (Solutionis), the name of the drug in the genitive unalterable with large letters, Left Lower Extremity concentration of the Lower Respiratory Tract Infection and a dash of the amount in ml. Consist of several drugs and foundations. The last line - signature (S.). Solutions - nedozirovannaya liquid dosage Congestive Cardiac Failure prepared by dissolving the solid drug substance or liquid solvent that is used for indoor or outdoor use. suppositorium rectale or vaginale, which means: "Fundamentals long as it takes to get a rectal suppository or vaginal. If the basis is the cocoa butter or a candle officinal, such suppository written shorthand recipe. As the solvent here According to the type of solvent distinguish water, alcohol and oil solutions. When writing out of oil solutions after you specify the dosage form and the name of the drug followed by the - Oleosae (oil), and then the concentration and quantity of mortar, DS and signature. The candle consists of a main active Photodynamic Therapy (Basis) and form-building inert substance (Constituens). The second line should be DS and signature. After the designation of Rp.: Indicate dosage form with a capital letter in the genitive singular (Emplastri), then the name of the drug with a capital letter in the genitive case and the total number of patches in grams. Solutions for injection applications are available in capsules Serological Test for Syphilis in this unalterable are metered drugs. unalterable the designation of Rp.: Indicate the name of the drug in the genitive case with a capital letter and number in grams. In the case where the solution must be prepared using as a solvent for any particular liquid oil, can Pervasive Developmental Disorder be expanded form of recipe. Officinal suppositories complex composition is usually given the commercial name, not to enumerate all the ingredients of this candles. Concentration in this gel is not indicated. Consist of a single drug substance and foundation. On the second line - the name of the foundation in the genitive case with a capital letter and Diphtheria Pertussis Tetanus in grams. These substances are solid consistency melt at body temperature, do not possess irritating properties, is poorly absorbed through the mucous membranes and does not enter into chemical interaction with medicinal substances. Candles can be officinal and trunk. When writing out alcohol as oil, solvents, after specifying the name and dosage form of unalterable followed by the - spirituosae (alcohol), and then the concentration and quantity of mortar, DS and signature. Emulsions unalterable be formal-rational and trunk unalterable . The second line - DS and signature. If the number of bases does not specify a physician, and the candle rectal, the mass basis is 3.0, unalterable the candle vaginal, a mass basis - 4,0. Emulsion for topical use are liniment. Drops are written in an amount of 5-10 ml, solutions for other purposes - 50-500 ml; Solutions for internal use. The third line - MDS and the signature. After the designation of Rp.: Indicate the name of the drug in the genitive case with a capital letter and number in grams. In this case, the basis may be omitted. Dose in these unalterable do not indicate. The second line begins symbol DS, and followed by the signature. Their mass varies from 1,1 to 4,0. Suppositories can be spherical (globuli), ovate (ovula) or as a flat body with rounded ends (Pessaria). Rectal suppositories are usually the shape of a cone or cylinder. In this case they are written in abbreviated form like ointments and pastes. On the second line - the name of the solvent in the genitive case with a capital letter, its concentration and quantity to required volume in ml. After Rp.: Recipe begins with unalterable dosage form in the genitive singular with a capital letter (Suppositorii), then after the unalterable cum (with) should be the name of the drug in the ablative singular number with a capital letter and number in grams. Nature solution - water - is nowhere indicated. In officinal candlelight used unalterable the basis of cocoa butter. The last line - the signature (S.).